Navigation Links
New drug improves survival in multiple myeloma relapse, Moffitt Cancer Center researchers say

Researchers at Moffitt Cancer Center and colleagues have investigated the safety, efficacy and the maximum tolerated dose of pomalidomide for patients with multiple myeloma who have disease relapsed after treatments with other drugs, such as bortezomib and lenalidomide. This phase I clinical trial enrolled 38 patients, and pomalidomide provided a minimal or better response for 42 percent of the patients, a partial response or better for 21 percent, and a complete response for 3 percent.

The study, a collaborative effort among researchers from Moffitt, Dana-Farber Cancer Institute, Hackensack University Medical Center, Multiple Myeloma Research Consortium, and Celgene Corporation, appeared in the Dec. 14 issue of Blood, the journal of the American Society of Hematology.

According to the authors, almost all multiple myeloma patients treated with bortezomib, lenalidomide or thalidomide relapse, and survival times shorten progressively with each subsequent relapse. Effective new treatments that re-establish tumor response are urgently required to improve outcomes for these patients.

"This open-label, phase I, dose-escalation study was primarily conducted to evaluate the maximum tolerated dose of pomalidomide," said study co-author Daniel Sullivan, M.D., associate center director for clinical investigations at Moffitt. "The secondary objective was to assess safety of pomalidomide when given with or without dexamethasone."

The researchers found that pomalidomide, given in escalating doses (from 2 to 5 mg per day for 21 of 28 days) in combination with low doses of dexamethasone, demonstrated "encouraging activity with manageable toxicity." The researchers noted that there was a low incidence of peripheral neuropathy in their study patients, all of whom had eventually failed past treatment with drugs known to be associated with neurotoxicity. Common adverse events included neutropenia, anemia, thrombocytopenia and fatigue. These adverse events were generally manageable and are not unexpected in this clinical situation.

Ongoing phase II studies have confirmed the safety and efficacy of this drug in patients with relapsed myeloma. The Food and Drug Administration is considering the drug for approval for this patient population.


Contact: Kim Polacek
H. Lee Moffitt Cancer Center & Research Institute

Related medicine news :

1. Novel gene-searching software improves accuracy in disease studies
2. Gene expression improves the definition of a breast cancer subtype
3. Combination of imaging exams improves Alzheimers diagnosis
4. Palliative care improves outcomes for seniors
5. Metformin improves blood glucose levels and BMI in very obese children
6. New Treatment Aids Weight Loss, Improves Diabetes in Monkeys
7. Networks it takes a village approach improves dementia care and informs research, study shows
8. 1 week at a health spa improves your health, study shows
9. First-of-its-kind program improves outcomes for seniors admitted for trauma
10. California improves its ranking on March of Dimes Annual Preterm Birth Report Card
11. Smart drug improves survival in older patients with acute myeloid leukemia
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ActivePDF, a ... PDF automation tool to batch conversions of CAD drawings, plans, and diagrams ... fidelity. , CADConverter eliminates the complexity requirement of specialized applications to view CAD ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... the world’s first commercially-available next-generation sequencing laboratory test for bacterial vaginosis- a ... and Obstetrics in Vancouver, BC, Canada. , In a presentation entitled: ...
(Date:10/12/2015)... ... October 13, 2015 , ... ... biannual Heroes in Recovery Awards at Foundations Recovery Network’s Moments of Change conference ... the one-of-a-kind awards to Noah Levine and Dean Dauphinais who exemplify the ideals ...
(Date:10/12/2015)... CA (PRWEB) , ... October 12, 2015 , ... According to an article ... data from adults today versus those of a similar group taken in 1988 has shown ... that a person in 2008 with the same diet as someone in 1971 would be ...
(Date:10/12/2015)... ... October 12, 2015 , ... Amerec , a leader in ... and skin care equipment, will be displaying custom sauna and steam room solutions at ... high-end resorts and spas as customers, SpaEquip is recognized for their ability to assist ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... Oct. 12, 2015  CME Group,s Center for Innovation ... CEO of Theranos, is the 11 th recipient of ... the revolutionary blood diagnostics company, Theranos , to change ... in a new era of preventive care. CME Group will ... Leadership Conference in Naples, Florida , ...
(Date:10/12/2015)... , October 12, 2015 ... - Pipeline Review, H2 2015 market research report ... R&D pipelines by identifying new targets and MOAs ... . --> ... pipeline spread across 62 pages, analyzing 6 companies, ...
(Date:10/12/2015)... VALLEY COTTAGE, New York , October 12, 2015 /PRNewswire/ ... Market Insights (FMI) delivers key insights on the global vital ... Signs Monitoring Devices Market: Global Industry Analysis and Opportunity Assessment ... to expand at a healthy CAGR of 9.5% and 9.2% ... period, due to factors, regarding which FMI offers major insights ...
Breaking Medicine Technology: